Patents by Inventor Peter Hofer

Peter Hofer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10358468
    Abstract: The present invention relates to a pharmaceutical composition comprising complement split product C4d for use in treating an inflammatory condition, such as graft rejection, graft versus host disease, an autoimmune disease or atopy. The C4d to be used may be a multimer. Accordingly, also C4d multimers and their use in medicine, like the treatment of inflammatory conditions, is provided. Furthermore, the present invention provides a protein complex comprising C4d interacting with its ILT4 receptor. This protein complex may be used in screening methods Also antibodies specifically binding to the C4d multimer or the C4d/ILT4-protein complex are subject of the present invention.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: July 23, 2019
    Assignee: Medizinische Universität Wien
    Inventors: Johannes Hofer, Peter Steinberger, Gerhard Zlabinger, Georg Böhmig, Florian Forster, Judith Leitner, Markus Wahrmann, Margarethe Merio, Johannes Kovarik, Markus Hölzl, David E. Isenman
  • Publication number: 20190214606
    Abstract: A plurality of battery cells arranged as a cell stack with adjacent lateral walls forming a row includes a case including two lateral walls from among the lateral walls, and a cap assembly capping the case, and including a positive terminal and a negative terminal, and a solid state switch arranged as an element in the cell stack of battery cells and for switchably connect the battery module with an external power grid, the solid state switch including a switch circuit board including a power MOSFET for providing a power stage for performing switching, a back cover and a front cover, the back and front covers forming a housing of the solid state switch and including lateral walls in the same size and shape as the lateral walls of the case of each battery cell.
    Type: Application
    Filed: June 26, 2018
    Publication date: July 11, 2019
    Inventors: Peter KURCIK, Maximilian HOFER, Helmut HAMMERSCHMIED, Markus PRETSCHUH
  • Publication number: 20190172026
    Abstract: Disclosed are computing devices, systems, methods to operate a cross blockchain secure token transaction engine to identify a set of one or more tokens of a first blockchain, lock the identified set of the one or more tokens of the first blockchain, and generate, based upon the locked set of the one or more tokens, a set of one or more tokens of a second blockchain, where the set of one or more tokens of the second blockchain are to be subsequently converted to tokens of the first blockchain based upon the locked set of tokens of the first blockchain.
    Type: Application
    Filed: November 30, 2018
    Publication date: June 6, 2019
    Inventors: Peter Joseph Vessenes, Philip Hofer
  • Patent number: 8658130
    Abstract: Suggested are agrochemical compositions, comprising (a) biocides, and (b) alkoxylation products of di- and/or oligosaccharide esters.
    Type: Grant
    Filed: February 4, 2010
    Date of Patent: February 25, 2014
    Assignee: Cognis IP Management GmbH
    Inventors: Hans-Georg Mainx, Peter Hofer
  • Publication number: 20110294667
    Abstract: Suggested are agrochemical compositions, comprising (a) biocides, and (b) alkoxylation products of di- and/or oligosaccharide esters.
    Type: Application
    Filed: February 4, 2010
    Publication date: December 1, 2011
    Inventors: Hans-Georg Mainx, Peter Hofer
  • Publication number: 20110251383
    Abstract: Suggested is an improved process for making polyol esters with improved colour quality by transesterification of polyols or their alkoxylation products with fatty acid alkyl esters, which is characterised in that the reaction is carried out in the presence of a reducing mineral or organic acid as a catalyst selected from the group consisting of (i) sulphuric or sulphonic acids with an oxidation value of sulphur of less than 6 or their salts, and/or (ii) phosphoric or phosphonic acids with an oxidation value of phosphor of less than 5 or their salts.
    Type: Application
    Filed: December 11, 2009
    Publication date: October 13, 2011
    Applicant: Cognis IP Management GmbH
    Inventors: Hans-Georg Mainx, Peter Hofer, Stefan Busch, Eike Ulf Mahnke
  • Publication number: 20100292191
    Abstract: The invention is related to alkylene oxide adducts of oligosaccharides, obtained by a process comprising alkoxylating at least one water-soluble oligosaccharide in aqueous solution at a temperature in the range of 90 to 160° C. The compounds are useful as adjuvants in agrochemical compositions.
    Type: Application
    Filed: December 11, 2008
    Publication date: November 18, 2010
    Applicant: COGNIS IP MANAGEMENT GMBH
    Inventors: Hans-Georg Mainx, Peter Hofer
  • Patent number: 7586305
    Abstract: In a method for determining an absolute number of electron spins in an extended sample (3) with the assistance of an apparatus for measuring magnetic resonance, the extended sample (3) is disposed within a measurement volume (2) of a radiofrequency RF resonator (1) of the apparatus during an electron spin resonance measurement (ESR).
    Type: Grant
    Filed: September 17, 2008
    Date of Patent: September 8, 2009
    Assignee: Bruker Biospin GmbH
    Inventors: Peter Höfer, Patrick Carl
  • Publication number: 20090079429
    Abstract: In a method for determining an absolute number of electron spins in an extended sample (3) with the assistance of an apparatus for measuring magnetic resonance, the extended sample (3) is disposed within a measurement volume (2) of a radiofrequency RF resonator (1) of the apparatus during an electron spin resonance measurement (ESR).
    Type: Application
    Filed: September 17, 2008
    Publication date: March 26, 2009
    Applicant: Bruker BioSpin GmbH
    Inventors: Peter Hofer, Patrick Carl
  • Publication number: 20030073834
    Abstract: The present invention comprises compounds having the general formula I: 1
    Type: Application
    Filed: February 1, 2002
    Publication date: April 17, 2003
    Inventors: David J. Cavalla, Mark Chasin, Peter Hofer
  • Patent number: 6440979
    Abstract: Disclosed are compounds having formula (II): wherein: Q3, Q6a, Q6b and Q8 are independently a bond, C1-8 alkylene, C2-8 alkenylene and C2-8 alkynylene, and R3, R6a, R6b and R8 are independently hydrogen, aryl or heteroraryl, optionally substituted by halogen, hydroxy, alkoxy, nitro, cyano and carboxy, provided that: Q3R3 is not hydrogen or methyl. The compounds are effective PDE IV inhibitors and possess improved PDE IV inhibition and improved selectivity with regard to PDE III inhibition.
    Type: Grant
    Filed: April 12, 2000
    Date of Patent: August 27, 2002
    Assignee: Euro-Celtique, S.A.
    Inventors: David Cavalla, Peter Hofer, Mark Chasin
  • Patent number: 6413975
    Abstract: Disclosed are compounds of the formula: wherein R3, R6a, R6b and R8 are substituted as disclosed herein. The compounds are effective in effecting PDE IV inhibition in patients in need thereof.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: July 2, 2002
    Assignee: Euro-Celtique, S.A.
    Inventors: Mark Chasin, David J. Cavalla, Peter Hofer, Andre Gehrig, Peter Wintergerst
  • Patent number: 6372770
    Abstract: Novel compounds which are effective PDE IV inhibitors are disclosed. The compounds possess improved PDE IV inhibition as compared to theophylline or rolipram, with improved selectivity with regard to, e.g., PDE III inhibition.
    Type: Grant
    Filed: September 11, 1998
    Date of Patent: April 16, 2002
    Assignee: Euro-Celtique, S.A.
    Inventors: Mark Chasin, David Cavalla, Peter Hofer, Lloyd Dolby
  • Patent number: 6365606
    Abstract: Novel compounds which are effective PDE IV inhibitors are disclosed. The compounds possess improved PDE IV inhibition compared to theophylline or rolipram, with improved selectivity with regard to, e.g., PDE V inhibition. The present invention includes compounds of Formula I: wherein the substituents are as disclosed herein.
    Type: Grant
    Filed: February 18, 2000
    Date of Patent: April 2, 2002
    Assignee: Euro-Celtique, S.A.
    Inventors: David Cavalla, Peter Hofer, Andre Gehrig, Peter Wintergerst, Mark Chasin
  • Patent number: 6319928
    Abstract: A compound of the formula: wherein R2 is O or S; R3, R6a and R8 are the same or different and each represent a C1-8 alkyl which is unbranched or branched and unsubstituted or substituted with OH, alkoxy, CO2H, ═NOH, ═NOCONH2, or ═O; C3-8 cycloalkyl which is unsubstituted or substituted with OH, alkoxy, CO2H, ═NOH, ═NOCONH2, or ═O; C4-8 cycloalkylalkyl wherein the cycloalkyl portion is unsubstituted or substituted with OH, alkoxy, CO2H, ═NOH, ═NOCONH2, or ═O; aryl which is unsubstituted or substituted with Cl, NH2, alkylamino, dialkylamino, amido, C1-C8 alkylamido, C1-C3 dialkylamido, OH, alkoxy, HC═NOH, HC═NOCONH2, C1-C3 alkyl, phenyl or benzyl; aralkyl (C1-4); heterocyclyl; heterocyclylalkyl (C1-C4); and heteroaryl; R6b represents a H or R6a, or together R6b, N, and R6a make a 3 to 8 member ring containing at least one carbon, from one to three nitrogen atoms, from zero to two oxygen atoms, from zero to two sulfur atoms, said ring op
    Type: Grant
    Filed: October 14, 1999
    Date of Patent: November 20, 2001
    Assignee: Euro-Celtique, S.A.
    Inventors: Mark Chasin, David J. Cavalla, Peter Hofer, Peter Wintergerst, Andre Gehrig
  • Patent number: 6314199
    Abstract: A process and an apparatus for the examination, especially the quality control, of optical components, in which an image of the particular component to be examined is produced and flaws in the imaged article are detected by image analysis, as well as the integration of that examining process into the manufacture of the component. The optical components may be optical components for the eye, such as spectacle lenses, contact lenses, intraocular lenses and the like.
    Type: Grant
    Filed: February 14, 1994
    Date of Patent: November 6, 2001
    Assignee: Novartis AG
    Inventors: Peter Höfer, Peter Hagmann, Roland Hauck, Wolfgang Geissler, Hubert Lutz
  • Patent number: 6310205
    Abstract: Hypoxanthine compounds of the structure: are disclosed where R3 and R8 are as described herein. The compounds are useful as intermediates to compounds providing PDE IV inhibition activity.
    Type: Grant
    Filed: January 26, 1999
    Date of Patent: October 30, 2001
    Assignee: Euro-Celtique, S.A.
    Inventors: Mark Chasin, Peter Hofer, David Cavalla
  • Patent number: 6294541
    Abstract: A compound of the formula: wherein R3 represent a C1-8 alkyl which is unbranched or branched and unsubstituted or substituted with OH, alkoxy, CO2H, ═NOH, ═NOCONH2, or ═O; C3-8 cycloalkyl which is unsubstituted or substituted with OH, alkoxy, CO2H, ═NOH, ═NOCONH2, or ═O; C4-8 cycloalkylalkyl wherein the cycloalkyl portion is unsubstituted or substituted with OH, alkoxy, CO2H, ═NOH, ═NOCONH2, or ═O; aryl which is unsubstituted or substituted with Cl, NH2, alkylamino, dialkylamino, amido, C1-C8 alkylamido, C1-C3 dialkylamido, OH, alkoxy, HC═NOH, HC═NOCONH2, C1-C3 alkyl, phenyl or benzyl; aralkyl (C1-4); heterocyclyl; heterocyclylalkyl (C1-C4); and heteroaryl; R8 represents H or a C1-8 alkyl which is unbranched or branched and unsubstituted or substituted with OH, alkoxy, CO2H, ═NOH, ═NOCONH2, or ═O; C3-8 cycloalkyl which is unsubstituted or substituted with OH, alkoxy, CO2H, ═NOH, ═NOCONH2, or ═O; C4-8 cyclo
    Type: Grant
    Filed: October 14, 1999
    Date of Patent: September 25, 2001
    Assignee: Euro-Celtique S.A.
    Inventors: David J. Cavalla, Mark Chasin, Peter Hofer, Andre Gehrig, Peter Wintergerst
  • Patent number: 6268373
    Abstract: Disclosed is a compound selected from the group consisting of 1,3,8-triethyl-2,6-dithioxanthine; 1,3,8-triethyl-2-thioxanthine; 8-cyclopropyl-1-ethyl-3-(2-methyl-butyl)-6-thioxanthine; 1,3-diethyl-8-isopropyl-6-thioxanthine; 8-cyclopropyl-1,3-dipropyl-6-thioxanthine; 8-isopropyl-1,3-dipropyl-6-thioxanthine; 1,3-diethyl-8-cyclopropyl-2,6-dithioxanthine; 1-(4-chlorobenzyl)-3-ethyl-8-isopropyl-6-thioxanthine; and 8-cyclopropyl-1,3-diethyl-6-thioxanthine. Also disclosed is a pharmaceutical composition comprising at least one pharmaceutically acceptable carrier and a compound selected from the group above. Also disclosed is a method of effecting PDE IV inhibition which comprises administering to a patient suffering from a disease or disorder selected from the group consisting of asthma, allergies, PDE IV modulated inflammation, and depression, a therapeutically effective amount of a compound selected from the group above.
    Type: Grant
    Filed: July 26, 1999
    Date of Patent: July 31, 2001
    Assignee: Euro-Celtique S.A.
    Inventors: David Cavalla, Peter Hofer, Mark Chasin
  • Patent number: 6248746
    Abstract: With the above and other objects in view, the present invention comprises compounds having the general formula (I): wherein: R1 is a C2-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 cycloalkyl, C3-8 cycloalkenyl or cycloalkynyl, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl or cycloalkynyl is optionally substituted with hydroxy, C1-5 alkoxy, C3-5 cycloalkoxy, halogen, oxo, carbamido, hydroxycarbamido, oximido, C1-5 alkyloximido, C3-5 cycloalkyloximido, C1-5 acyloximido or C3-5 cycloacyloximido; Q is methylene or ethylene; R3 is aryl or heteroaryl wherein said aryl or heteroaryl has one to three substituents selected from the group consisting of C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C3-6 cycloalkenyl, cycloalkynyl, C3-5 alkylene, C3-5 cycloalkylene, haloC1-6 alkyl, haloC1-6 cycloalkyl, hydroxy, C1-5 alkoxy, C3-5 cycloalkoxy, C1-2 alkylenedioxy, C1-6 acyl, C3-6 cycloacyl, C1-6 acyloxy, C3-6 cycloacyloxy, halogen, nitro or cyano; R8 is C1-5 alkyl or C3-5 cycl
    Type: Grant
    Filed: January 7, 1999
    Date of Patent: June 19, 2001
    Assignee: Euro-Celtique S.A.
    Inventors: Mark Chasin, David J. Cavalla, Peter Hofer